Fierce Biotech Week
Biotech

BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug

After axing its lead obesity asset, BioAge has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses
Will Maddox May 14, 2026 11:00am
positive negative up down good bad mixed

Biogen advances Alzheimer’s tau program despite midphase miss

May 14, 2026 8:35am
syneos-herov2-04302026png

MRD as a Decision Engine: Rethinking Oncology Trial Design

Brought to you by Syneos Health
Child jumping on trampoline

Regenxbio reaps pivotal win for Duchenne gene therapy

May 14, 2026 7:25am
Terminated contract

Aptose exits cancer pact after Hanmi buyout blocks development

May 14, 2026 6:35am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

AC Immune CEO bids adieu—Chutes & Ladders

May 15, 2026 8:30am
More News

Alumis pulls back from would-be rival to Amgen’s Tepezza

May 15, 2026 3:44am

Aardvark to dig into phase 3 data early after FDA imposes hold

May 15, 2026 1:51am

Signant Health buys Ametris to unite data streams in trials

May 14, 2026 1:27pm
Fierce Pharma

Biopharma rallies behind Pazdur to lead FDA. But is he willing?

May 14, 2026 11:05am